{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:08:09Z","timestamp":1788952089735,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Dose finding and optimization studies are important in oncology drug development for making new drugs available to patients at pace and for reducing the risk of toxicity. The requirement by Project Optimus to conduct a randomized dose optimization study necessitates a change in the oncology drug development paradigm, and standard dose-response modeling approaches (e.g., Multiple Comparisons Procedure-Modeling, MCP-Mod) are not always applicable due to small sample sizes and a small number of doses that are typical of dose optimization studies. An innovative Bayesian model averaging method for dose ranging studies (BAMADOS) is proposed for the design and analysis of oncology trials with binary endpoints. The method assumes a monotonic relationship between response and doses of an investigational drug. It does not require pre-specification of candidate models but instead evaluates all possible models in a constrained model space. To minimize the potential impact of the Occam\u2019s razor property, non-conjugate moderately informative priors from the family of generalized normal priors are implemented. We show via simulation studies that BAMADOS correctly identifies the optimal biological dose in a dose optimization setting. It further estimates response rates with little bias, even in the presence of discordance between the priors and observed data. Compared to MCP-Mod, BAMADOS exhibited higher power for small sample sizes (30 or fewer participants per dose) and comparable power for larger sample sizes in several scenarios considered.<\/jats:p>","DOI":"10.1093\/biomtc\/ujag156","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:35:21Z","timestamp":1787657721000},"source":"Crossref","is-referenced-by-count":0,"title":["A Bayesian model averaging method for dose ranging studies in oncology"],"prefix":"10.1093","volume":"82","author":[{"given":"Adetayo","family":"Kasim","sequence":"first","affiliation":[{"name":"Oncology Biostatistics , GlaxoSmithKline,\u00a0Stevenage, SG1 2NY ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-0119","authenticated-orcid":false,"given":"Nathan W","family":"Bean","sequence":"additional","affiliation":[{"name":"Quantitative Sciences Innovation , GlaxoSmithKline,\u00a0Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parkhomenko","sequence":"additional","affiliation":[{"name":"Oncology Biostatistics , GlaxoSmithKline,\u00a0Stevenage, SG1 2NY ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Cottle","sequence":"additional","affiliation":[{"name":"Oncology Biostatistics , GlaxoSmithKline,\u00a0Stevenage, SG1 2NY ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Acusta","sequence":"additional","affiliation":[{"name":"Oncology Biostatistics , GlaxoSmithKline, Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Oncology Biostatistics , GlaxoSmithKline, Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Tsang","family":"Chen","sequence":"additional","affiliation":[{"name":"Asia Development , GlaxoSmithKline, Tokyo,\u00a0171-0014 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Sabin","sequence":"additional","affiliation":[{"name":"Oncology Biostatistics , GlaxoSmithKline,\u00a0Stevenage, SG1 2NY ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A","family":"Psioda","sequence":"additional","affiliation":[{"name":"Quantitative Sciences Innovation , GlaxoSmithKline,\u00a0Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2026090905370333300_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/rssc.12255","article-title":"BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity","volume":"67","author":"Chu","year":"2018","journal-title":"Journal of the Royal Statistical Society Series C: Applied Statistics"},{"key":"2026090905370333300_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"2","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"2026090905370333300_bib3","article-title":"Qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty","author":"European Medicines Agency EMA","year":"2014"},{"key":"2026090905370333300_bib4","article-title":"Statistical review and evaluation qualification of statistical approach: MCP-Mod","author":"Food and Drug Administration, U.S.FDA","year":"2016"},{"key":"2026090905370333300_bib5","volume-title":"gnorm: Generalized Normal\/Exponential Power Distribution","author":"Griffin","year":"2018"},{"key":"2026090905370333300_bib6","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/biom.13840","article-title":"DROID: Dose-ranging approach to optimizing dose in oncology drug development","volume":"79","author":"Guo","year":"2023","journal-title":"Biometrics"},{"key":"2026090905370333300_bib7","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/cancers12041010","article-title":"Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events","volume":"12","author":"Iwamoto","year":"2020","journal-title":"Cancers"},{"key":"2026090905370333300_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/10543406.2022.2078346","article-title":"A structured framework for adaptively incorporating external evidence in sequentially monitored clinical trials","volume":"32","author":"Kwiatkowski","year":"2022","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"2026090905370333300_bib9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s43441-019-00014-4","article-title":"Reducing patient burden in clinical trials through the use of historical controls: Appropriate selection of historical data to minimize risk of bias","volume":"54","author":"Lim","year":"2019","journal-title":"Therapeutic Innovation and Regulatory Science"},{"key":"2026090905370333300_bib10","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/PO.20.00257","article-title":"BOIN12: Bayesian optimal interval phase I\/II trial design for utility-based dose finding in immunotherapy and targeted therapies","volume":"54","author":"Lin","year":"2020","journal-title":"JCO Precision Oncology"},{"key":"2026090905370333300_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.12793\/tcp.2022.30.e9","article-title":"FDA initiatives to support dose optimization in oncology drug development: The less may be the better","volume":"30","author":"Moon","year":"2022","journal-title":"Translational and Clinical Pharmacology"},{"key":"2026090905370333300_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/02664760500079464","article-title":"A generalized normal distribution","volume":"32","author":"Nadarajah","year":"2005","journal-title":"Journal of Applied Statistics"},{"key":"2026090905370333300_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1214\/aos\/1056562461","article-title":"Slice sampling","volume":"31","author":"Neal","year":"2003","journal-title":"The Annals of Statistics"},{"key":"2026090905370333300_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10543406.2014.919931","article-title":"A flexible Bayesian approach for modeling monotonic dose\u2013response relationships in drug development trials","volume":"25","author":"Ohlssen","year":"2015","journal-title":"Journal of Biopharmaceutical Statistics"},{"key":"2026090905370333300_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/19466315.2013.855472","article-title":"Dose\u2013response modeling under simple order restrictions using Bayesian variable selection methods","volume":"6","author":"Otava","year":"2014","journal-title":"Statistics in Biopharmaceutical Research"},{"key":"2026090905370333300_bib16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/sim.6052","article-title":"Model-based dose finding under model uncertainty using general parametric models","volume":"33","author":"Pinheiro","year":"2014","journal-title":"Statistics in Medicine"},{"key":"2026090905370333300_bib17","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/sj.bjc.6605030","article-title":"Clinical benefit in phase-I trials of novel molecularly targeted agents: Does dose matter?","volume":"100","author":"Postel-Vinay","year":"2009","journal-title":"British Journal of Cancer"},{"key":"2026090905370333300_bib18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology\u2013when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"2026090905370333300_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/sim.9237","article-title":"Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers","volume":"41","author":"Takeda","year":"2021","journal-title":"Statistics in Medicine"},{"key":"2026090905370333300_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pst.1589","article-title":"Use of historical control data for assessing treatment effects in clinical trials","volume":"13","author":"Viele","year":"2014","journal-title":"Pharmaceutical Statistics"},{"key":"2026090905370333300_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/17407745231207085","article-title":"Statistical and practical considerations in planning and conduct of dose-optimization trials","volume":"21","author":"Yuan","year":"2024","journal-title":"Clinical Trials"},{"key":"2026090905370333300_bib22","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.22.00371","article-title":"Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients","volume":"40","author":"Zirkelbach","year":"2022","journal-title":"Journal of Clinical Oncology"}],"container-title":["Biometrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/82\/3\/ujag156\/71005223\/ujag156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/82\/3\/ujag156\/71005223\/ujag156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:10:25Z","timestamp":1788948625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biometrics\/article\/doi\/10.1093\/biomtc\/ujag156\/8788692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/biomtc\/ujag156","relation":{},"ISSN":["0006-341X","1541-0420"],"issn-type":[{"value":"0006-341X","type":"print"},{"value":"1541-0420","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"ujag156"}}